Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells

Abbasifard, Mitra; Kamiab, Zahra; Hasani, Motahareh; Rahnama, Amir; Saeed-Askari, Pooya; Khorramdelazad, Hossein

doi:10.1186/s12865-020-00388-3

Cited by 13 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs could inhibit B cells differentiation into plasma cells and antibody production via soluble factors and cell–to–cell contact involving the PD-1/PD ligand pathway ( 35 , 36 ). Regulatory B cells (Bregs) exert immunosuppressive functions at least partly through the production of IL-10 and TGF-β in SLE ( 38 , 39 ). MSCs can induce the expansion of Bregs and inhibit excessive inflammatory responses in a murine lupus model ( 33 ).…”

Section: Molecular Mechanisms Of Mscs In Slementioning

confidence: 99%

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

Guo

Pan

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Although previous studies have demonstrated that SLE is related to the imbalance of cells in the immune system, including B cells, T cells, and dendritic cells, etc., the mechanisms underlying SLE pathogenesis remain unclear. Therefore, effective and low side-effect therapies for SLE are lacking. Recently, mesenchymal stem cell (MSC) therapy for autoimmune diseases, particularly SLE, has gained increasing attention. This therapy can improve the signs and symptoms of refractory SLE by promoting the proliferation of Th2 and Treg cells and inhibiting the activity of Th1, Th17, and B cells, etc. However, MSC therapy is also reported ineffective in some patients with SLE, which may be related to MSC- or patient-derived factors. Therefore, the therapeutic effects of MSCs should be further confirmed. This review summarizes the status of MSC therapy in refractory SLE treatment and potential reasons for the ineffectiveness of MSC therapy from three perspectives. We propose various MSC modification methods that may be beneficial in enhancing the immunosuppression of MSCs in SLE. However, their safety and protective effects in patients with SLE still need to be confirmed by further experimental and clinical evidence.

show abstract

Section: Molecular Mechanisms Of Mscs In Slementioning

confidence: 99%

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

Guo

Pan

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…IL-10 is synthesized by Breg when the bond between IFN-α and CD40 occurs. An increase in the severity of SLE which is marked by an increase in the SLEDAI score will be followed by a decrease in IL-10 and TGF-β levels [15]. IL-10 is a cytokine that has a complex heterodimer receptor.…”

Section: Discussionmentioning

confidence: 99%

“…The results showed that serum levels of IL-10 and TGF-β decreased significantly with increasing SLEDAI scores in the patients studied (P <0.05). It was concluded that the release of antiinflammatory cytokines, especially IL-10 and TGF-β, can inhibit the immune response and autoreactive immune cells in SLE patients with mild to moderate disease activity [15].…”

Section: Discussionmentioning

confidence: 99%

Effect of Red Bean Extract (Phaseolus vulgaris L.) on IL-10 Levels in Systemic Lupus Erythematosus Model

Mukhamad Nooryanto,

Tatit Nurseta,

Cholid Rohman Riskianto

et al. 2023

a-jhr

View full text Add to dashboard Cite

Introduction: Systemic Lupus Erythematosus (SLE) is a is a chronic autoimmune inflammatory disease of unknown etiologic. Multiorgan dysfunction in women with SLE causes menstrual irregularities, ovarian failure, follicular atresia, and premature ovarian failure (POF) leading to the cessation of menstruation. Phaseolus vulgaris L. contains isoflavones that can trigger oocyte maturation, stimulate the formation of antral follicles, increase FSH receptor expression and proliferate cell nuclear antigen (PCNA) expression. This study aims to prove the effect of red bean extract (isoflavones) in SLE by and increasing the secretion of anti-inflammatory IL-10 levels. Material and Methods: This study used a true experimental design with a post-test-only controlled group design. The samples used in this study were at least 25 female Balb/c mice. Data on serum IL-10 levels in mice were obtained by measurement using ELISA. The data were statistically analysed using SPSS 16 for Windows software program. The data were tested for normality and homogeneity using parametric non-parametric analysis. Results: The results showed that there was a significant difference in ANA levels with a p-value of 0.000 in each sample. From this test, it was proven that there was a significant increase in IL-10 levels at doses of 75 mg/KgBW (P2) and 100 mg/KgBW (P3) (p-value=0.000) due to the administration of various doses of red bean extract (isoflavones). Conclusion: Red bean extract (isoflavones) had a significant effect in increasing IL-10 levels.

show abstract

“…Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory connective tissue disorder that affects multiple organs [ 1 ]. The production of pathogenic autoantibodies and irregular immune responses are involved in the pathogenesis of SLE which leads to clinical and serological manifestations [ 2 , 3 ]. The disease has a wide range of clinical manifestations, including rash, oral ulcer, arthralgia, and life-threatening involvement of internal organs, the most common of which is lupus nephritis [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study

Abbasifard

Khorramdelazad

Rostamian

et al. 2023

Trials

Self Cite

View full text Add to dashboard Cite

Backgrounds N-acetylcysteine (NAC) has broadly been used as an anti-oxidant agent in various types of diseases. This study aimed to assess the effect of NAC on the systemic lupus erythematosus (SLE) disease activity and outcome. Methods In this randomized, double-blind clinical trial study, 80 SLE patients were recruited that were classified into two groups: 40 patients received NAC (1800 mg/day; 3 times per day with 8-h intervals) for 3 months and 40 patients as the control group received normal therapies. Laboratory measurements and disease activity based on the British Isles Lupus Assessment Group (BILAG) and SLE Disease Activity Index (SLEDAI) were determined before the initiation of treatment and after the study time period. Results A statistically significant decrease in BILAG (P= 0.023) and SLEDAI (P= 0.034) scores after receiving NAC for a 3-month period was observed. BILAG (P= 0.021) and SLEDAI (P= 0.030) scores were significantly lower in NAC-receiving patients compared to the control group after 3 months. The disease activity in each organ based on BILAG score after treatment indicated a significant decrease in the NAC group compared to the baseline level in general (P=0.018), mucocutaneous (P=0.003), neurological (P=0.015), musculoskeletal (P=0.048), cardiorespiratory (P=0.047), renal (P=0.025), and vascular (P=0.048) complications. Analysis indicated a significant increase in CH50 level in the NAC group after treatment compared to the baseline level (P=0.049). No adverse event was reported by the study subjects. Conclusions It appears that the administration of 1800 mg/day NAC to SLE patients can decrease the SLE disease activity and its complications.

show abstract

Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells

Cited by 13 publications

References 31 publications

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

Effect of Red Bean Extract (Phaseolus vulgaris L.) on IL-10 Levels in Systemic Lupus Erythematosus Model

Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study

Contact Info

Product

Resources

About